Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Terminated 21 enrolled TG Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.

Timeline

Start: 2021-04-28
Primary completion: 2024-06-12
Completion: 2024-06-12

Publications

Chauchet X, Cons L, Chatel L, Daubeuf B, Didelot G, Moine V, Chollet D, Malinge P, Pontini G, Masternak K, Ferlin W, Buatois V, Shang L. CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model. Exp Hematol Oncol. 2022 May 10;11(1):26. doi: 10.1186/s40164-022-00279-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ublituximab	Monoclonal antibody	25 mg/ml	Intravenous
Subject	ZERIPATAMIG	Monoclonal antibody	—	—

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Summary

Timeline

Publications

Drugs

Indications